98 related articles for article (PubMed ID: 26970274)
21. Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor.
Carsol JL; Gingras S; Simard J
Mol Endocrinol; 2002 Jul; 16(7):1696-710. PubMed ID: 12089361
[TBL] [Abstract][Full Text] [Related]
22. Dominant negative variants of the SHP-2 tyrosine phosphatase inhibit prolactin activation of Jak2 (janus kinase 2) and induction of Stat5 (signal transducer and activator of transcription 5)-dependent transcription.
Berchtold S; Volarevic S; Moriggl R; Mercep M; Groner B
Mol Endocrinol; 1998 Apr; 12(4):556-67. PubMed ID: 9544991
[TBL] [Abstract][Full Text] [Related]
23. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
Lim JH; Kim TY; Kim WH; Park JW
Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
[TBL] [Abstract][Full Text] [Related]
24. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a negative transcriptional element in the BRCA1 promoter.
MacDonald G; Stramwasser M; Mueller CR
Breast Cancer Res; 2007; 9(4):R49. PubMed ID: 17663789
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 is differentially expressed in human tumor cells.
Meng QH; Yuan RQ; Goldberg ID; Rosen EM; Fan SJ
Shi Yan Sheng Wu Xue Bao; 2001 Mar; 34(1):55-64. PubMed ID: 12549011
[TBL] [Abstract][Full Text] [Related]
27. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter.
Chai YL; Cui J; Shao N; Shyam E; Reddy P; Rao VN
Oncogene; 1999 Jan; 18(1):263-8. PubMed ID: 9926942
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins.
Fan S; Wang JA; Yuan RQ; Ma YX; Meng Q; Erdos MR; Brody LC; Goldberg ID; Rosen EM
Oncogene; 1998 Jun; 16(23):3069-82. PubMed ID: 9662340
[TBL] [Abstract][Full Text] [Related]
29. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
Yeung BH; Kwan BW; He QY; Lee AS; Liu J; Wong AS
Oncogene; 2008 Dec; 27(53):6782-9. PubMed ID: 18776923
[TBL] [Abstract][Full Text] [Related]
30. S179D prolactin sensitizes human prostate cancer cells such that physiological concentrations of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death.
Wu W; Zanello L; Walker AM
Prostate; 2007 Oct; 67(14):1498-506. PubMed ID: 17680631
[TBL] [Abstract][Full Text] [Related]
31. Regulation of the rat liver sodium-dependent bile acid cotransporter gene by prolactin. Mediation of transcriptional activation by Stat5.
Ganguly TC; O'Brien ML; Karpen SJ; Hyde JF; Suchy FJ; Vore M
J Clin Invest; 1997 Jun; 99(12):2906-14. PubMed ID: 9185514
[TBL] [Abstract][Full Text] [Related]
32. AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines.
Privat M; Aubel C; Arnould S; Communal Y; Ferrara M; Bignon YJ
Anticancer Res; 2010 Jun; 30(6):2049-54. PubMed ID: 20651350
[TBL] [Abstract][Full Text] [Related]
33. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 interacts with dominant negative SWI/SNF enzymes without affecting homologous recombination or radiation-induced gene activation of p21 or Mdm2.
Hill DA; de la Serna IL; Veal TM; Imbalzano AN
J Cell Biochem; 2004 Apr; 91(5):987-98. PubMed ID: 15034933
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 physically associates with p53 and stimulates its transcriptional activity.
Zhang H; Somasundaram K; Peng Y; Tian H; Zhang H; Bi D; Weber BL; El-Deiry WS
Oncogene; 1998 Apr; 16(13):1713-21. PubMed ID: 9582019
[TBL] [Abstract][Full Text] [Related]
36. The cyclin-dependent kinase inhibitor, p21(WAF1), promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells.
Kuljaca S; Liu T; Dwarte T; Kavallaris M; Haber M; Norris MD; Martin-Caballero J; Marshall GM
Carcinogenesis; 2009 Nov; 30(11):1865-71. PubMed ID: 19773351
[TBL] [Abstract][Full Text] [Related]
37. TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.
Peng Y; Dai H; Wang E; Lin CC; Mo W; Peng G; Lin SY
Cancer Res; 2015 Jan; 75(2):378-86. PubMed ID: 25480944
[TBL] [Abstract][Full Text] [Related]
38. Alteration of BRCA1 expression affects alcohol-induced transcription of RNA Pol III-dependent genes.
Zhong Q; Shi G; Zhang Y; Lu L; Levy D; Zhong S
Gene; 2015 Feb; 556(1):74-9. PubMed ID: 25447904
[TBL] [Abstract][Full Text] [Related]
39. hRAD9 functions as a tumor suppressor by inducing p21-dependent senescence and suppressing epithelial-mesenchymal transition through inhibition of Slug transcription.
Wen FC; Chang TW; Tseng YL; Lee JC; Chang MC
Carcinogenesis; 2014 Jul; 35(7):1481-90. PubMed ID: 24403312
[TBL] [Abstract][Full Text] [Related]
40. Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells.
Kehn K; Berro R; Alhaj A; Bottazzi ME; Yeh WI; Klase Z; Van Duyne R; Fu S; Kashanchi F
Oncogene; 2007 Aug; 26(35):5060-9. PubMed ID: 17334399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
